Orbimed Advisors LLC Immuno Gen, Inc. Transaction History

Orbimed Advisors LLC

$4.15 Billion
Q2 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$4.26 - $7.48 $16.5 Million - $28.9 Million	-3,868,786 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$4.75 - $7.5 $52.4 Million - $82.7 Million	-11,029,128 Reduced 74.03%	3,868,786 $28.7 Million
Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $9.85 Million - $12.9 Million	1,961,292 Added 15.16%	14,897,914 $84.5 Million
Q2 2021 Aug 16, 2021	BUY	$5.79 - $8.6 $22 Million - $32.7 Million	3,804,800 Added 41.67%	12,936,622 $85.3 Million
Q1 2021 May 17, 2021	BUY	$6.5 - $10.53 $42.8 Million - $69.3 Million	6,577,922 Added 257.56%	9,131,822 $74 Million
Q4 2020 Feb 16, 2021	BUY	$3.7 - $7.66 $9.45 Million - $19.6 Million	2,553,900 New	2,553,900 $16.5 Million
Q1 2020 May 15, 2020	SELL	$2.12 - $6.8 $608,016 - $1.95 Million	-286,800 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.25 - $5.8 $645,300 - $1.66 Million	286,800 New	286,800 $1.46 Million
Q4 2018 Feb 14, 2019	SELL	$3.94 - $9.7 $5.79 Million - $14.3 Million	-1,469,189 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$8.6 - $11.26 $12.3 Million - $16.2 Million	-1,435,081 Reduced 49.41%	1,469,189 $13.9 Million
Q2 2018 Aug 14, 2018	BUY	$9.52 - $12.15 $13.3 Million - $17 Million	1,400,000 Added 93.07%	2,904,270 $28.3 Million
Q1 2018 May 15, 2018	SELL	$6.7 - $12.95 $8.91 Million - $17.2 Million	-1,329,856 Reduced 46.92%	1,504,270 $15.8 Million
Q4 2017 Feb 14, 2018	SELL	$5.07 - $7.92 $13.3 Million - $20.7 Million	-2,616,455 Reduced 48.0%	2,834,126 $18.2 Million
Q3 2017 Nov 14, 2017	BUY	$5.4 - $8.47 $29.4 Million - $46.2 Million	5,450,581	5,450,581 $41.7 Million

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.

Account